Clearmind Medicine Inc. and SciSparc Ltd. have partnered to conduct a study on the combination treatment of obesity and metabolic syndrome, using Clearmind's MEAI and SciSparc's Palmitoylethanolamide (PEA). The research agreement has been entered into with the Hebrew University of Jerusalem, led by Professor Joseph Tam. A previous pre-clinical study showed that obese animals treated with MEAI demonstrated increased energy expenditure, better fat utilization, weight loss of 20%, improved glucose tolerance, as well as reduced fat and triglyceride accumulation in the liver.
Clearmind is a biotech company focused on discovering novel psychedelic-derived therapeutics to solve major under-treated health problems while SciSparc is a specialty clinical-stage pharmaceutical company focusing on developing therapies to treat disorders of the central nervous system.
The upcoming study will evaluate the effect of the combination of MEAI and PEA on food intake, metabolic and activity profiles. Keywords: Clearmind Medicine, SciSparc, study, combination treatment, obesity, metabolic syndrome
Clearmind Medicine Inc. and SciSparc Ltd